Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.861 USD | +0.42% | -8.01% | -9.94% |
Apr. 16 | Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration | MT |
Apr. 16 | Transcript : Precision BioSciences, Inc. - Special Call |
Financials (USD)
Sales 2024 * | 21.17M | Sales 2025 * | 21.46M | Capitalization | 67.92M |
---|---|---|---|---|---|
Net income 2024 * | -50M | Net income 2025 * | -60M | EV / Sales 2024 * | 0.26 x |
Net cash position 2024 * | 62.43M | Net cash position 2025 * | 135M | EV / Sales 2025 * | -3.12 x |
P/E ratio 2024 * |
-1.33
x | P/E ratio 2025 * |
-2.1
x | Employees | 109 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Latest transcript on Precision BioSciences, Inc.
1 day | -4.01% | ||
1 week | -14.68% | ||
Current month | -27.58% | ||
1 month | -15.49% | ||
3 months | -9.07% | ||
6 months | +13.34% | ||
Current year | -10.32% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Amoroso
CEO | Chief Executive Officer | 46 | 21-10-14 |
Jeff Smith
FOU | Founder | - | 06-01-25 |
John Kelly
DFI | Director of Finance/CFO | 57 | 20-10-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kevin Buehler
CHM | Chairman | 66 | 19-11-07 |
Geno Germano
BRD | Director/Board Member | 63 | 20-03-09 |
Director/Board Member | 75 | 21-11-05 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.16% | 2 M€ | -25.75% | ||
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 9.861 | +0.42% | 8 711 |
24-04-24 | 9.82 | -4.01% | 33,626 |
24-04-23 | 10.23 | +5.68% | 31,106 |
24-04-22 | 9.68 | -0.62% | 47,192 |
24-04-19 | 9.74 | -9.14% | 170,634 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
- Stock Market
- Equities
- DTIL Stock